Vincent JL, et al. – In this investigation involving patients with sepsis-associated coagulopathy, researchers determined the impact of human recombinant thrombomodulin vs placebo on 28-day all-cause mortality. The study was completed by 800 of 816 randomized patients, who were included in the full analysis set. Overall, the administration of human recombinant thrombomodulin did not significantly reduce 28-day all-cause mortality vs placebo in patients with sepsis-associated coagulopathy.